Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Hepatic steatosis (HS) identified on CT may provide an integrated cardiometabolic and COVID-19 risk assessment. This study presents a deep-learning-based hepatic fat assessment (DeHFt) pipeline for (a) more standardised measurements and (b) investigating the association between HS (liver-to-spleen attenuation ratio <1 in CT) and COVID-19 infections severity, wherein severity is defined as requiring invasive mechanical ventilation, extracorporeal membrane oxygenation, death.
Methods: DeHFt comprises two steps. First, a deep-learning-based segmentation model (3D residual-UNet) is trained (N.ß=.ß80) to segment the liver and spleen. Second, CT attenuation is estimated using slice-based and volumetric-based methods. DeHFt-based mean liver and liver-to-spleen attenuation are compared with an expert's ROI-based measurements. We further obtained the liver-to-spleen attenuation ratio in a large multi-site cohort of patients with COVID-19 infections (D1, N.ß=.ß805; D2, N.ß=.ß1917; D3, N.ß=.ß169) using the DeHFt pipeline and investigated the association between HS and COVID-19 infections severity.
Findings: The DeHFt pipeline achieved a dice coefficient of 0.95, 95% CI [0.93...0.96] on the independent validation cohort (N.ß=.ß49). The automated slice-based and volumetric-based liver and liver-to-spleen attenuation estimations strongly correlated with expert's measurement. In the COVID-19 cohorts, severe infections had a higher proportion of patients with HS than non-severe infections (pooled OR.ß=.ß1.50, 95% CI [1.20...1.88], P.ß<.ß.001).
Interpretation: The DeHFt pipeline enabled accurate segmentation of liver and spleen on non-contrast CTs and automated estimation of liver and liver-to-spleen attenuation ratio. In three cohorts of patients with COVID-19 infections (N.ß=.ß2891), HS was associated with disease severity. Pending validation, DeHFt provides an automated CT-based metabolic risk assessment.
Funding: For a full list of funding bodies, please see the Acknowledgements.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605693 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2022.104315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deep learning-based automated assessment of hepatic fibrosis via magnetic resonance images and nonimage data.
Quant Imaging Med Surg
September 2025
Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Accurate staging of hepatic fibrosis is critical for prognostication and management among patients with chronic liver disease, and noninvasive, efficient alternatives to biopsy are urgently needed. This study aimed to evaluate the performance of an automated deep learning (DL) algorithm for fibrosis staging and for differentiating patients with hepatic fibrosis from healthy individuals via magnetic resonance (MR) images with and without additional clinical data.
Methods: A total of 500 patients from two medical centers were retrospectively analyzed.
Automated AI-based segmentation of canine hepatic focal lesions from CT studies.
Front Vet Sci
August 2025
Department of Animal Medicine, Production and Health, University of Padua, Padua, Italy.
Introduction: Hepatic masses are a common occurrence in veterinary medicine, with treatment options largely dependent on the nature and location of the mass. The gold standard treatment involves surgical removal of the mass, often followed by chemotherapy if necessary. However, in cases where mass removal is not feasible, chemotherapy becomes the primary treatment option.
View Article and Find Full Text PDFMRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approach.
Eur Radiol Exp
August 2025
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Background: We aimed to quantify hepatic vessel volumes across chronic liver disease stages and healthy controls using deep learning-based magnetic resonance imaging (MRI) analysis, and assess correlations with biomarkers for liver (dys)function and fibrosis/portal hypertension.
Methods: We assessed retrospectively healthy controls, non-advanced and advanced chronic liver disease (ACLD) patients using a 3D U-Net model for hepatic vessel segmentation on portal venous phase gadoxetic acid-enhanced 3-T MRI. Total (TVVR), hepatic (HVVR), and intrahepatic portal vein-to-volume ratios (PVVR) were compared between groups and correlated with: albumin-bilirubin (ALBI) and "model for end-stage liver disease-sodium" (MELD-Na) score) and fibrosis/portal hypertension (Fibrosis-4 (FIB-4) Score, liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), platelet count (PLT), and spleen volume.
Ultra-low-dose hepatic computed tomography with a novel real-time deep learning-based noise reduction algorithm: a prospective cross-sectional analysis of image quality and lesion detection.
Quant Imaging Med Surg
August 2025
Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: Contrast-enhanced computed tomography (CT) is essential for tumor assessment, but the detection of low-contrast liver lesions remains challenging. Reducing the radiation dose increases image noise, compromising image quality and diagnostic accuracy. Iterative reconstruction (IR) algorithms can reduce noise; however, they can also alter image texture and limit lesion detection.
View Article and Find Full Text PDFEarly prediction of adverse outcomes in liver cirrhosis using a CT-based multimodal deep learning model.
Abdom Radiol (NY)
June 2025
Department of Radiology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, China.
Purpose: Early-stage cirrhosis frequently presents without symptoms, making timely identification of high-risk patients challenging. We aimed to develop a deep learning-based triple-modal fusion liver cirrhosis network (TMF-LCNet) for the prediction of adverse outcomes, offering a promising tool to enhance early risk assessment and improve clinical management strategies.
Methods: This retrospective study included 243 patients with early-stage cirrhosis across two centers.